The insider sales are routine and small relative to market cap, driven by option exercises and tax planning. No bearish signal. Monitor for any upcoming pipeline catalysts (Nurix is a clinical-stage biotech) that could move the stock independent of insider activity.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Aug 5 $25.12entry
- T+1 · 3mo ago +0.40%α +0.56% · $25.22
- T+5 · 3mo ago +6.01%α +5.66% · $26.63
- T+20 · due 3mo ago Pending
- T+60 · due 19d ago Pending
Price Chart
How similar events traded
Executive Summary
Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) sold a total of ~$515K in open-market sales over a 7-day window, with the CLO's sale of $382K dominating the cluster. The sales are modest relative to the $2.4B market cap (~0.02%), and the CFO's and CSO's sales follow option exercises, suggesting tax/vesting-related liquidity rather than a bearish signal. The cluster is neutral given the small dollar amount and routine pattern of exercise-and-sell transactions.
Key Financial Metrics
Key Facts
- Three C-suite insiders (CFO, CSO, CLO) sold shares in open-market transactions totaling ~$515K.
- The largest sale was by CLO Christine Ring: 16,589 shares at $23.05 for $382K on 2026-08-03.
- CFO Hans van Houte sold 2,967 shares at $24.65 and 1,794 shares at $23.89, totaling ~$116K.
- CSO Gwenn Hansen sold 3,847 shares at $23.38 for ~$90K on 2026-07-30.
- All three insiders also exercised stock options (non-cash) on 2026-07-30, indicating the sales are likely for tax withholding or diversification.
- Total open-market sales represent ~0.02% of NRIX's $2.4B market cap, trivial in proportion.
Financial Impact
Total open-market insider sales of ~$515K, representing ~0.02% of market cap, immaterial.
Risk Factors
- Insider sales could accelerate if the stock continues to rise, but current pattern is non-informative.
- Clinical-stage biotech risk: any negative pipeline readout could overshadow insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1785894116182 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers